Karimpour-razkenari, 31 patient melatonin ICU study: 39% lower mortality [p=0.37], 43% shorter ventilation [p=0.13], and 2% shorter ICU admission [p=0.85] https://c19p.org/karimpourrazkenari
copied to clipboard
Melatonin as adjunctive therapy in patients admitted to the Covid-19
et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103492
Retrospective 31 ICU patients, 12 treated with melatonin, showing lower mortality with treatment, without statistical significance. Melatonin 15mg daily.
|
risk of death, 39.0% lower, HR 0.61, p = 0.37, treatment 5 of 12 (41.7%), control 13 of 19 (68.4%), NNT 3.7, Kaplan–Meier.
|
|
ventilation time, 42.9% lower, relative time 0.57, p = 0.13, treatment 12, control 19.
|
|
ICU time, 1.9% lower, relative time 0.98, p = 0.85, treatment 12, control 19.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Karimpour-razkenari et al., 10 Mar 2022, retrospective, Iran, peer-reviewed, 6 authors, study period 13 March, 2020 - 30 May, 2020.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.